peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

IGF-1 splice variant

MGF

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

PEG-MGF (pegylated mechano growth factor) is categorized in the abstract as an IGF-1 analogue within peptides used to modulate the GH–IGF-1 axis.

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

PEG-MGF (pegylated mechano growth factor) is categorized in the abstract as an IGF-1 analogue within peptides used to modulate the GH–IGF-1 axis.

Sources[1]pubmedThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)).
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)).”

    The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. · Abstract

    pubmed:42395176:9df538e1edba:9df538e1edba

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 3 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (1), assurance_score_below_0.72 (2), current_regulatory_source_required (1), extraction_ambiguity (3), high_risk_requires_regulatory_or_two_independent_sources (2), no_direct_support (3)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-17T23:10:15Z

Publication history and provenance

Version 1 · Automated assessment · 2026-08-17T23:10:15Z

f27a93893347c15de0818faba278e7f0193082a33ff433aa5ac7dae4ebc2df7b